[go: up one dir, main page]

 
 
Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Journals

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Article Types

Countries / Regions

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Search Results (944)

Search Parameters:
Keywords = HOMA-IR

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
16 pages, 1550 KiB  
Article
Obesity-Related Complications Including Dysglycemia Based on 1-h Post-Load Plasma Glucose in Children and Adolescents Screened before and after COVID-19 Pandemic
by Joanna Smyczyńska, Aleksandra Olejniczak, Paulina Różycka, Aneta Chylińska-Frątczak, Arkadiusz Michalak, Urszula Smyczyńska, Beata Mianowska, Iwona Pietrzak and Agnieszka Szadkowska
Nutrients 2024, 16(15), 2568; https://doi.org/10.3390/nu16152568 - 5 Aug 2024
Viewed by 516
Abstract
Childhood obesity, with its metabolic complications, is a problem of public health. The International Diabetes Federation (IDF) has recommended glucose levels 1 h post oral glucose load (1h-PG) > 155–209 mg/dL as diagnostic for intermediate hyperglycemia (IH), while >209 mg/dL for type 2 [...] Read more.
Childhood obesity, with its metabolic complications, is a problem of public health. The International Diabetes Federation (IDF) has recommended glucose levels 1 h post oral glucose load (1h-PG) > 155–209 mg/dL as diagnostic for intermediate hyperglycemia (IH), while >209 mg/dL for type 2 diabetes (T2D). The aim of the study was to assess the occurrence of prediabetes, IH, and T2D in children and adolescents with simple obesity according to the criteria of American Diabetes Association (ADA) and of IDF, and the effect of COVID-19 pandemic on these disorders. Analysis included 263 children with simple obesity, screened either in prepandemic (PRE—113 cases) or post-pandemic period (POST—150 cases). All children underwent 2 h OGTT with measurements of glucose and insulin every 0.5 h, lipid profile, and other tests; indices if insulin resistance (IR): HOMA, QUICKI, Matsuda index, AUC (glu/ins) were calculated. The incidence of T2D, prediabetes, and IH was higher in POST with respect to PRE, with significant differences in the indices of IR, except for HOMA. Significant differences were observed in the assessed parameters of glucose metabolism among the groups with T2D, prediabetes, IH, and normal glucose tolerance (NGT), with some similarities between IH (based on 1h-PG) and prediabetes. Increased frequency of dysglycemia among children and adolescents with simple obesity is observed after COVID-19 pandemic. Metabolic profile of patients with IH at 1h-PG is “intermediate” between NGT and prediabetes. Full article
(This article belongs to the Section Nutrition and Diabetes)
Show Figures

Figure 1

Figure 1
<p>Glucose (<b>a</b>) and insulin (<b>b</b>) concentrations during OGTT in the patients diagnosed before (PRE) and after (POST) the COVID-19 pandemic. Glucose and insulin concentrations are expressed as median values (column) and interquartile range (whiskers). Significant differences: a, c—<span class="html-italic">p</span> &lt; 0.001, b—<span class="html-italic">p</span> = 0.024, d—<span class="html-italic">p</span> = 0.031.</p>
Full article ">Figure 2
<p>Percentage of the patients with T2D, prediabetes, and NGT according to the criteria of ADA in groups PRE (<b>a</b>) and POST (<b>b</b>).</p>
Full article ">Figure 3
<p>Percentage of the patients with T2D, prediabetes, IH-1h, and NGT according to the criteria of IDF in groups PRE (<b>a</b>) and POST (<b>b</b>).</p>
Full article ">Figure 4
<p>Glucose (<b>a</b>) and insulin (<b>b</b>) concentrations during OGTT in the patients with T2D, prediabetes, and NGT, diagnosed according to the criteria of ADA. Glucose and insulin concentrations are expressed as median values (column) and interquartile range (whiskers). Significant differences in post hoc tests: a, b—<span class="html-italic">p</span> = 0.007, c—<span class="html-italic">p</span> = 0.002, d–i—<span class="html-italic">p</span> = &lt;0.001, k—<span class="html-italic">p</span> = 0.04, m—<span class="html-italic">p</span> = 0.004, n—<span class="html-italic">p</span> &lt; 0.001.</p>
Full article ">Figure 5
<p>Glucose (<b>a</b>) and insulin (<b>b</b>) concentrations during OGTT in the patients diagnosed with T2D, prediabetes, IH-1h, and NGT according to the criteria of IDF. Glucose and insulin concentrations are expressed as median values (column) and interquartile range (whiskers). Significant differences in post hoc tests: a—<span class="html-italic">p</span> = 0.03, b—<span class="html-italic">p</span> = 0.002, c—<span class="html-italic">p</span> = 0.02, d–l—<span class="html-italic">p</span> &lt; 0.001, m—<span class="html-italic">p</span> = 0.005, n–p,r—<span class="html-italic">p</span> &lt; 0.001, s—<span class="html-italic">p</span> = 0.003, t–x—<span class="html-italic">p</span> &lt; 0.001, y—<span class="html-italic">p</span> = 0.04.</p>
Full article ">Figure 6
<p>Glucose (<b>a</b>) and insulin (<b>b</b>) profiles of particular patients with T2D diagnosed according to the criteria of ADA [<a href="#B8-nutrients-16-02568" class="html-bibr">8</a>] or IDF only [<a href="#B13-nutrients-16-02568" class="html-bibr">13</a>].</p>
Full article ">
13 pages, 428 KiB  
Article
Branched-Chain and Aromatic Amino Acids, Type 2 Diabetes, and Cardiometabolic Risk Factors among Puerto Rican Adults
by Sona Rivas-Tumanyan, Lorena S. Pacheco, Danielle E. Haslam, Evangelia Morou-Bermudez, Liming Liang, Katherine L. Tucker, Kaumudi J. Joshipura and Shilpa N. Bhupathiraju
Nutrients 2024, 16(15), 2562; https://doi.org/10.3390/nu16152562 - 4 Aug 2024
Viewed by 596
Abstract
(1) Background: Branched-chain and aromatic amino acids (BCAAs/AAAs) have been considered as markers of type 2 diabetes (T2D); however, studies on associations between these metabolites and T2D and cardiometabolic traits in Hispanic populations are limited. The aim of this study was to examine [...] Read more.
(1) Background: Branched-chain and aromatic amino acids (BCAAs/AAAs) have been considered as markers of type 2 diabetes (T2D); however, studies on associations between these metabolites and T2D and cardiometabolic traits in Hispanic populations are limited. The aim of this study was to examine the associations between baseline BCAAs (isoleucine, leucine, valine)/AAAs (phenylalanine, tyrosine) and prevalent and incident T2D, as well as baseline and longitudinal (2 year) changes in cardiometabolic traits (measures of glycemia, dyslipidemia, inflammation, and obesity) in two large cohorts of adults of Puerto Rican descent. (2) Methods: We included participants of the Boston Puerto Rican Health Study (BPRHS, n = 670) and San Juan Overweight Adult Longitudinal study (SOALS, n = 999) with available baseline metabolite and covariate data. T2D diagnosis was defined based on American Diabetes Association criteria. Multivariable logistic (for baseline T2D), Poisson (for incident T2D), and linear (for cardiometabolic traits) regression models were used; cohort-specific results were combined in the meta-analysis and adjusted for multiple comparisons. (3) Results: Higher baseline BCAAs were associated with higher odds of prevalent T2D (OR1SD BCAA score = 1.46, 95% CI: 1.34–1.59, p < 0.0001) and higher risk of incident T2D (IRR1SD BCAA score = 1.24, 95% CI: 1.13–1.37, p < 0.0001). In multivariable longitudinal analysis, higher leucine and valine concentrations were associated with 2-year increase in insulin (beta 1SD leucine = 0.37 mcU/mL, 95% CI: 0.11–0.63, p < 0.05; beta 1SD valine = 0.43 mcU/mL, 95% CI: 0.17–0.68, p < 0.01). Tyrosine was a significant predictor of incident T2D (IRR = 1.31, 95% CI: 1.09–1.58, p < 0.05), as well as 2 year increases in HOMA-IR (beta 1SD tyrosine = 0.13, 95% CI: 0.04–0.22, p < 0.05) and insulin concentrations (beta 1SD tyrosine = 0.37 mcU/mL, 95% CI: 0.12–0.61, p < 0.05). (4) Conclusions: Our results confirmed the associations between BCAAs and prevalent and incident T2D, as well as concurrent measures of glycemia, dyslipidemia, and obesity, previously reported in predominantly White and Asian populations. Baseline leucine, valine, and tyrosine were predictors of 2 year increases in insulin, whereas tyrosine was a significant predictor of deteriorating insulin resistance over time. Our study suggests that BCAAs and tyrosine could serve as early markers of future glycemic changes in Puerto Ricans. Full article
(This article belongs to the Section Proteins and Amino Acids)
Show Figures

Figure 1

Figure 1
<p>Associations between branched-chain amino acids and aromatic amino acids, and incident type 2 diabetes in the Boston Puerto Rican Health Study (BPRHS, <span class="html-italic">n</span> = 316) and San Juan Overweight Adult Longitudinal Study (SOALS, <span class="html-italic">n</span> = 924). FDR-adjusted <span class="html-italic">p</span>-value: * <span class="html-italic">p</span> &lt; 0.05; ** <span class="html-italic">p</span> &lt; 0.01; *** <span class="html-italic">p</span> &lt; 0.001; † <span class="html-italic">p</span> &lt; 0.0001. Incidence rate ratio estimates were obtained from Poisson regression models, using the log-transformed follow-up time as the offset variable. Branched-chain amino acid (BCAA) score is a combined metabolite score including leucine, isoleucine, and valine, weighted according to the strength of the association of each metabolite with T2D. Branched-chain amino acids and aromatic amino acids (BCAA-AAA) score is a combined metabolite score including leucine, isoleucine, valine, phenylalanine, and tyrosine, weighted according to the strength of the association of each metabolite with T2D. BPRHS multivariable model adjusted for age, sex, education, income, smoking, alcohol consumption, physical activity score, acculturation, perceived stress score, multivitamin use, anti-hypertensive and lipid-lowering medication use, American Heart Association diet score, 2-year change in waist circumference, and body mass index. SOALS multivariable model adjusted for age, sex, education, income, smoking, alcohol consumption, physical activity, anti-hypertensive and lipid-lowering medication use, 2-year change in waist circumference, and body mass index.</p>
Full article ">
12 pages, 921 KiB  
Article
Prevention Is Better than Cure—Body Composition and Glycolipid Metabolism after a 24-Week Physical Activity Program without Nutritional Intervention in Healthy Sedentary Women
by Ewa Śliwicka, Natalia Popierz-Rydlewska, Anna Straburzyńska-Lupa, Jivko Nikolov, Łucja Pilaczyńska-Szcześniak and Anna Gogojewicz
Nutrients 2024, 16(15), 2536; https://doi.org/10.3390/nu16152536 - 2 Aug 2024
Viewed by 597
Abstract
Women are generally less active than men; therefore, the search for an attractive form of physical activity that benefits women’s health is underway. This study aimed to investigate the influence of a 24-week physical activity program on body composition and indices of carbohydrates [...] Read more.
Women are generally less active than men; therefore, the search for an attractive form of physical activity that benefits women’s health is underway. This study aimed to investigate the influence of a 24-week physical activity program on body composition and indices of carbohydrates and lipid metabolism in sedentary, healthy women. The study comprised 18 female volunteers (mean age 35.0 ± 5.3 years). Dietary intake was assessed using a standardized seven-day food record. Before entering the program and after completing it, each participant’s body composition and indices of glycolipid metabolism were measured. Insulin resistance indexes were calculated based on the obtained data. After the physical activity program, significant decreases in body mass and composition, BMI, waist circumference, percentage of fat content, and fat mass were found. Moreover, there was a significant decrease in glucose, insulin, triglycerides (TG), and resistin concentrations, as well as in the mean values of HOMA-IR and HOMA-AD. A substantial increase in adiponectin levels was also found. To conclude, the combined endurance–resistance physical activity program had a beneficial effect on body mass and composition and improved carbohydrate and lipid metabolism in normal-weight, healthy women. Therefore, we recommend this activity to sedentary young women to prevent obesity and metabolic disorders. Full article
Show Figures

Figure 1

Figure 1
<p>Flowchart of the study selection process.</p>
Full article ">
11 pages, 4743 KiB  
Article
Extraction, Characterization, and Nutraceutical Potential of Prosthechea karwinskii Orchid for Insulin Resistance and Oxidative Stress in Wistar Rats
by Gabriela Soledad Barragán-Zarate, Luicita Lagunez-Rivera, Alfonso Alexander-Aguilera, Rodolfo Solano and Gerard Vilarem
Foods 2024, 13(15), 2432; https://doi.org/10.3390/foods13152432 - 1 Aug 2024
Viewed by 404
Abstract
Prosthechea karwinskii is an endemic orchid of Mexico with cultural significance for its ornamental, food, religious, and medicinal uses. In traditional medicine, diabetic patients use the leaves of this plant to lower glucose levels. The present study evaluated the effect of P. karwinskii [...] Read more.
Prosthechea karwinskii is an endemic orchid of Mexico with cultural significance for its ornamental, food, religious, and medicinal uses. In traditional medicine, diabetic patients use the leaves of this plant to lower glucose levels. The present study evaluated the effect of P. karwinskii leaves extract on the antioxidant enzymes superoxide dismutase (SOD) and catalase (CAT) in a model of obese rats with insulin resistance for its nutraceutical potential to reduce insulin resistance and oxidative stress. Obesity and insulin resistance were induced with 40% sucrose in water for 20 weeks. Four groups (control rats, obese rats, obese rats administered the extract, and obese rats administered metformin) were evaluated. Extract compounds were identified by UHPLC-ESI-qTOF-MS/MS. Glucose, insulin, triglyceride, and insulin resistance indices (HOMA-IR and TyG), as well as the activity of the antioxidant enzymes, increased in rats in the obese group. Administration of P. karwinskii extract and metformin reduced glucose, insulin, triglyceride, and insulin resistance indices and antioxidant enzyme activity to values similar to those of the control group. Therefore, this study shows the nutraceutical potential of P. karwinskii extract as an ingredient in the formulation of dietary supplements or functional foods to help treat diseases whose pathophysiology is related to oxidative stress and insulin resistance. Full article
Show Figures

Figure 1

Figure 1
<p>Glucose (<b>a</b>), insulin (<b>b</b>), and (<b>c</b>) triglyceride levels and HOMA-IR (<b>d</b>) and TyG (<b>e</b>) insulin resistance indices. Values expressed as means ± SDs. * Indicates a significant difference (<span class="html-italic">p</span> ˂ 0.05) with respect to CG; ** indicates a significant difference (<span class="html-italic">p</span> ˂ 0.05) with respect to OG. CG: control group, OG: obese rats, PK: obese rats that received extract, and MET: obese rats that received metformin.</p>
Full article ">Figure 2
<p>Superoxide dismutase enzyme activity (SOD) (<b>a</b>) and catalase enzyme activity (CAT) (<b>b</b>). Values expressed as means ± SDs. * Indicates a significant difference (<span class="html-italic">p</span> ˂ 0.05) with respect to GC; ** indicates a significant difference (<span class="html-italic">p</span> ˂ 0.05) with respect to OG. CG: control group, OG: obese rats, PK: obese rats that received extract, and MET: obese rats that received metformin.</p>
Full article ">
16 pages, 1287 KiB  
Article
Exploring the Association of Biochemical Characterization and Genetic Determinants of TNF-α, CXCR2, and CCR5 Delta 32 Mutation with Predisposition to Polycystic Ovary Syndrome
by Kholoud S. Almasoudi, Eram Hussain, Reema Almotairi, Tanzeela Bhat, Nabil Mtiraoui, Intissar Ezzidi and Rashid Mir
Life 2024, 14(8), 949; https://doi.org/10.3390/life14080949 - 28 Jul 2024
Viewed by 496
Abstract
PCOS is a heterogeneous, multifactorial endocrine disorder with a complex pathophysiology. It is a globally rising infertility disorder that affects a large percentage of women of reproductive age, with a relatively high prevalence of 8–13%. Genome-wide association studies have revealed associations of genetic [...] Read more.
PCOS is a heterogeneous, multifactorial endocrine disorder with a complex pathophysiology. It is a globally rising infertility disorder that affects a large percentage of women of reproductive age, with a relatively high prevalence of 8–13%. Genome-wide association studies have revealed associations of genetic variations with many diseases, including PCOS. The cellular activity of IL8 is mediated by the receptor CXCR2, and transcription of IL8 is controlled by TNF-α. Therefore, this study aimed to investigate the association of TNF-α, CCR5-delta32, and CXCR2 gene variations with PCOS. Methodology: In this case control study, we used amplification-refractory mutation system (ARMS)-PCR to detect and determine the presence of the polymorphic variants TNF-α, CCR5-delta32, and CXCR2 in the study subjects. These gene polymorphs may serve as critical candidate gene variants in PCOS pathogenesis and therapeutics. Results: The case–control study’s findings revealed that the majority of the biochemical and endocrine serum biomarkers examined in the investigation—including lipids (LDL, HDL, and cholesterol), T2DM markers (fasting glucose, free insulin, and HOMA-IR), and hormones (FSH, LH, testosterone, and progesterone)—exhibited statistically significant changes in PCOS patients. The distributions of TNF-α (rs1800629), CCR5-delta32, and CXCR2 (rs2230054) genotypes analyzed within PCOS patients and healthy controls in the considered population were significant (p < 0.05). The heterozygosity of CXCR2-CA, TNF-α GA, and CCR5(WT+Δ32*) genotypes was significantly associated with PCOS susceptibility, with high OR and p < 0.05 in the codominant model. Similarly, the A allele of the TNF-α and CXCR2 genes, along with the CCR5Δ32*(mutant) allele, was significantly associated with PCOS susceptibility, with high OR and p < 0.05. Likewise, the CXCR2 (CA+AA) vs CC genotype was associated with increased susceptibility to PCOS, with OR 2.25, p < 0.032. Conclusions: Our study concludes that TNF-α rs1800629G>A, CXCR2-rs2230054C>T, and CCR5-Delta32 rs333 are potential loci for developing PCOS in the Tabuk population. These findings might eventually be useful in identifying and classifying those who are at risk for PCOS. To validate these results, it is advised that further longitudinal studies be conducted in diverse ethnic populations and with larger sample sizes. Full article
(This article belongs to the Section Genetics and Genomics)
Show Figures

Figure 1

Figure 1
<p>Agarose gel electrophoresis of PCR products corresponding to mutation-specific PCR for CCR5 Δ32 bp deletion in PCOS patients. CCR5 Δ32 bp deletion: M-100 bp DNA ladder; Homozygous CCR5 Δ32 (+/+): P1, P2, P3, P4, P5, P6, P7, P8, P9, P11, P14, P17, P19; Heterozygous CCR5 Δ32 +/Δ P10, P12, P13, P15, P16. CCR5 Δ32; Homozygous Δ/Δ – 0.</p>
Full article ">Figure 2
<p>Agarose gel electrophoresis of PCR products corresponding to TNF-α rs1800629 G&gt;A genotyping in PCOS patients. TNF-α rs1800629 G&gt;A genotyping: M-100 bp DNA ladder; Homozygous-GG -P2, P4, P6, P7, P8, P9, P10, P11; Heterozygous-GA-P1, P3, P9, P12; Homozygous-AA-P5.</p>
Full article ">Figure 3
<p>Agarose gel electrophoresis of PCR products corresponding to CXCR2+785C&gt;T genotyping in PCOS patients. CXCR2+785C&gt;T (rs2230054) genotyping: M-DNA ladder-100 bp; Homozygous-CC-P1; Heterozygous CA-P2, P4, P5, P6; Homozygous-AA-P3, P7.</p>
Full article ">
16 pages, 2688 KiB  
Article
Morin Prevents Non-Alcoholic Hepatic Steatosis in Obese Rats by Targeting the Peroxisome Proliferator-Activated Receptor Alpha (PPARα)
by Laila Naif Al-Harbi
Life 2024, 14(8), 945; https://doi.org/10.3390/life14080945 - 28 Jul 2024
Viewed by 301
Abstract
Background: Obesity has become a widespread issue globally. Morin, a flavonoid with traditional use in managing hyperglycemia and hyperlipidemia, has demonstrated antioxidant and anti-inflammatory properties in experimental studies. This research aims to explore the anti-obesity potential of morin in rats subjected to a [...] Read more.
Background: Obesity has become a widespread issue globally. Morin, a flavonoid with traditional use in managing hyperglycemia and hyperlipidemia, has demonstrated antioxidant and anti-inflammatory properties in experimental studies. This research aims to explore the anti-obesity potential of morin in rats subjected to a high-fat diet (HFD) and investigate whether its effects are mediated through PPARα regulation. Methods: Young adult male Wistar albino rats were divided into four groups (n = 8/group): normal, morin (50 mg/kg/BWT, oral), HFD, and HFD + morin (50 mg/kg/BWT, oral). Treatments were administered daily for 17 consecutive weeks. Results: Morin mitigated the elevation in glucose levels and decreased fasting glucose and insulin levels, along with the HOMA-IR index, in HFD-fed rats. Furthermore, morin reduced calorie intake, final body weights, and the masses of subcutaneous, epididymal, peritoneal, and mesenteric fat in these rats. It also attenuated the rise in systolic blood pressure in HFD-fed rats and decreased serum levels of triglycerides, cholesterol, free fatty acids, LDL-c, and leptin, while increasing levels of HDL-c and adiponectin in both normal and HFD-fed rats. Moreover, morin restored normal liver structure and reduced fat vacuole accumulation in HFD-fed rats. Notably, it upregulated mRNA levels of PPARα in the livers and white adipose tissue of both normal and HFD-fed rats. Conclusions: These findings suggest the potential use of morin to enhance fatty acid oxidation in white adipose tissue and mitigate obesity, warranting further clinical investigation into its therapeutic applications. Full article
(This article belongs to the Section Animal Science)
Show Figures

Figure 1

Figure 1
<p>Food intake (<b>A</b>), calorie intake (<b>C</b>), changes in body weights (<b>E</b>), and their respective areas under the curve (<b>B</b>,<b>D</b>,<b>F</b>, respectively) were assessed in all groups of rats throughout the entire 17-week study period. The data are expressed as means ± standard deviation (<span class="html-italic">n</span> = 8/group). Significance levels are denoted as follows: a: compared to normal; b: compared to morin-treated normal rats (50 mg/kg); c: compared to HFD-fed rats.</p>
Full article ">Figure 1 Cont.
<p>Food intake (<b>A</b>), calorie intake (<b>C</b>), changes in body weights (<b>E</b>), and their respective areas under the curve (<b>B</b>,<b>D</b>,<b>F</b>, respectively) were assessed in all groups of rats throughout the entire 17-week study period. The data are expressed as means ± standard deviation (<span class="html-italic">n</span> = 8/group). Significance levels are denoted as follows: a: compared to normal; b: compared to morin-treated normal rats (50 mg/kg); c: compared to HFD-fed rats.</p>
Full article ">Figure 2
<p>Mesenteric fat (<b>A</b>), subcutaneous fat (<b>B</b>), peritoneal fat (<b>C</b>), and epididymal fats (<b>D</b>).The weights of various fat pads were measured across all rat groups. Data are expressed as means ± SD (<span class="html-italic">n</span> = 8/group). Statistical comparisons were made as follows: a: versus normal; b: versus morin-treated normal rats (50 mg/kg); c: versus HFD-fed rats.</p>
Full article ">Figure 3
<p>Plasma Glucose level (<b>A</b>), Urea under the curve (<b>B</b>), Fasting glucose level (<b>C</b>), Fasting insulin level (<b>D</b>), HOMA-IR (<b>E</b>). Blood glucose levels during the oral glucose tolerance test (OGTT) are depicted in panel <b>A</b>, with the corresponding area under the curve (AUC/B). Additionally, fasting levels of glucose, insulin, and HOMA-IR are presented for all groups of rats. The data are expressed as means ± SD (<span class="html-italic">n</span> = 8/group). Comparisons are indicated as follows: a: vs. normal; b: vs. morin-treated (50 mg/kg) normal rats; c: vs. HFD-fed rats.</p>
Full article ">Figure 4
<p>The levels of malondialdehyde (MDA) (<b>A</b>), total superoxide dismutase (SOD) (<b>B</b>), and total glutathione (GSH) (<b>C</b>) in the livers of all rat groups were assessed. Data are expressed as means ± standard deviation (SD) with eight rats per group. Statistical comparisons were made as follows: a, compared to normal rats; b, compared to morin-treated normal rats (50 mg/kg); c, compared to HFD-fed rats.</p>
Full article ">Figure 5
<p>mRNA levels of PPARα and CPT-1 in the liver (<b>A</b>,<b>C</b>) and white adipose tissues (WAT) (<b>B</b>,<b>D</b>) of all groups of rats. Data are presented as means ± SD (<span class="html-italic">n</span> = 8/group). <sup>a</sup>: vs. normal; <sup>b</sup>: vs. morin-treated normal rats (50 mg/kg); <sup>c</sup>: vs. HFD-fed rats).</p>
Full article ">Figure 6
<p>Liver histology was examined across all rat groups. (<b>A</b>,<b>B</b>) represent samples from normal rats and those treated with morin, respectively, depicting typical features such as hepatocytes (short arrow), the central vein (CV), and sinusoids (long arrow). (<b>C</b>), derived from an HFD model rat, illustrates pronounced and severe fatty vacuoles within hepatocyte cytoplasm (long arrow). In contrast, (<b>D</b>), from an HFD + morin-treated rat, displays considerable improvement in liver structure. Most hepatocytes appear normal (short arrow), with few fat vacuoles present. However, some regions exhibit signs of cell necrosis (long arrow).</p>
Full article ">
18 pages, 2360 KiB  
Article
Black Tea Kombucha Consumption: Effect on Cardiometabolic Parameters and Diet Quality of Individuals with and without Obesity
by Gabriela Macedo Fraiz, Mirian A. C. Costa, Rodrigo R. Cardoso, James R. Hébert, Longgang Zhao, Viviana Corich, Alessio Giacomini, Fermín I. Milagro, Frederico A. R. Barros and Josefina Bressan
Fermentation 2024, 10(8), 384; https://doi.org/10.3390/fermentation10080384 - 26 Jul 2024
Viewed by 483
Abstract
Background: Kombucha, a fermented tea, has been suggested as an adjuvant in the treatment of obesity. Although animal and in vitro studies indicate its promising benefits, exploring kombucha’s impact on human health is necessary. Methods: This quasi-experimental pre–post-intervention assessed the effect of black [...] Read more.
Background: Kombucha, a fermented tea, has been suggested as an adjuvant in the treatment of obesity. Although animal and in vitro studies indicate its promising benefits, exploring kombucha’s impact on human health is necessary. Methods: This quasi-experimental pre–post-intervention assessed the effect of black tea kombucha consumption on cardiometabolic parameters for 8 weeks, considering the quality of the diet of individuals with and without obesity. Diet quality was assessed through the Dietary Inflammatory Index® and Dietary Total Antioxidant Capacity. Paired t-test/Wilcoxon was applied to compare differences between pre- and post-intervention (α = 0.05). Results: After the intervention, individuals with obesity showed a decrease in insulin, HOMA-IR, and GGT; those without obesity showed an increase in total cholesterol and alkaline phosphatase, but this was only observed in those with a worsened diet quality. Conclusion: kombucha intake demonstrated positive impacts on the metabolic health of individuals with obesity beyond the importance of combining it with healthy eating patterns. Full article
Show Figures

Figure 1

Figure 1
<p>Illustration of the experimental design of the study. This intervention lasted eight weeks. Participants had to drink 200 mL/day of kombucha and maintain their usual diet and physical activity pattern throughout the study. Blood samples and a Food Frequency Questionnaire were collected at the beginning and end of the study. BIA: bioimpedance body composition analysis; IPAQ International Physical Activity Questionnaire; FFQ: Food Frequency Questionnaire; ICF: informed consent form; TFEQ: Three-Factor Eating Questionnaire.</p>
Full article ">Figure 2
<p>Step-by-step process of black tea kombucha production. It was produced using 12 g of black tea and 50 g of crystal sugar for each liter of drinking water. The black tea leaves were steeped for 5 min after the drinking water reached 95 °C. Then, the tea was strained and cooled until it reached 25 °C. Once cooled, 3% of SCOBY was added to the total volume of black tea produced. Additionally, 100 mL/L of previously produced kombucha was also added in order to reduce the pH and, thus, inhibit the growth of pathogenic microorganisms. Fermentation was carried out in a BOD (Biochemical Oxygen Demand) incubator for temperature control (25 °C) for seven days. After fermentation, the kombucha was strained, packed in 200 mL PET bottles, and stored in a refrigerator until it was distributed to the participants.</p>
Full article ">Figure 3
<p>Flowchart of study participants selection. In the online pre-screening, 193 people responded to the form, and of these, 62 passed the screening eligibility criteria and were invited to a face-to-face screening. Of these, 46 met the inclusion criteria and were selected to participate in the study, 23 in each group. In the group without obesity, two individuals were excluded due to suspected or confirmed infection of SARS-CoV-2, and one withdrew for personal reasons. In the obesity group, seven individuals did not complete all stages, two were excluded due to antibiotics use, and the others withdrew for personal reasons.</p>
Full article ">Figure 4
<p>Illustration comparing cardiometabolic markers at the beginning and end of the study, according to allocation group (without and with obesity). Data expressed as means with SEM for total cholesterol, ALP, and GGT (normal distribution, paired <span class="html-italic">t</span>-test) and medians with interquartile range for insulin and HOMA-IR (without normal distribution, Wilcoxon test). Significance expressed by * <span class="html-italic">p</span> &lt; 0.05. Orange color: participants without obesity and pink color: participants with obesity. ALP: alkaline phosphatase; GGT: gamma-glutamyl transferase.</p>
Full article ">Figure 5
<p>Illustration comparing main cardiometabolic markers, according to the variation in the Dietary Inflammatory Index (DII) and obesity status between the end and beginning of the study. Data expressed as means with SEM for total cholesterol (normal distribution, paired <span class="html-italic">t</span>-test) and medians with interquartile range for insulin and HOMA-IR (without normal distribution, Wilcoxon test). Significance expressed by * <span class="html-italic">p</span> &lt; 0.05, <span class="html-italic">t</span> = tendency &lt; 0.1. Orange/beige color: participants who increased/decreased DII. Pink/light-pink color: participants who increased/decreased DII.</p>
Full article ">Figure 6
<p>Illustration comparing main cardiometabolic markers, according to the variation in the Dietary Total Antioxidant Capacity (DTAC) and obesity status between the end and beginning of the study. Data expressed as means with SEM for total cholesterol (normal distribution, paired <span class="html-italic">t</span>-test) and medians with interquartile range for insulin and HOMA-IR (without normal distribution, Wilcoxon test). Significance expressed by * <span class="html-italic">p</span> &lt; 0.05, t = tendency &lt; 0.1. Orange/beige color: participants who increased/decreased DTAC. Pink/light-pink color: participants who increased/decreased DTAC.</p>
Full article ">
14 pages, 965 KiB  
Article
Altered Body Composition and Cytokine Production in Patients with Elevated HOMA-IR after SARS-CoV-2 Infection: A 12-Month Longitudinal Study
by Rona Kartika, Imam Subekti, Farid Kurniawan, Syahidatul Wafa, Tika Pradnjaparamita, Dicky L. Tahapary and Heri Wibowo
Biomedicines 2024, 12(7), 1581; https://doi.org/10.3390/biomedicines12071581 - 17 Jul 2024
Viewed by 462
Abstract
Altered body composition and cytokine production due to SARS-CoV-2 antigens may affect homeostasis model assessment for insulin resistance (HOMA-IR) after SARS-CoV-2 infection. To elucidate this phenomenon, we conducted a longitudinal study involving 47 COVID-19 patients, who were followed up for 12 months. During [...] Read more.
Altered body composition and cytokine production due to SARS-CoV-2 antigens may affect homeostasis model assessment for insulin resistance (HOMA-IR) after SARS-CoV-2 infection. To elucidate this phenomenon, we conducted a longitudinal study involving 47 COVID-19 patients, who were followed up for 12 months. During recruitment, body composition and glucose indices were measured, and heparin blood samples were collected for measuring cytokine production. HOMA-IR was considered an elevated or non-elevated group based on the ratio between HOMA-IR at 12 months and 1 month of convalescence. Those with elevated HOMA-IR had a significantly higher body mass index, body fat percentage, and visceral fat rating and had a lower lean mass and lean/fat mass ratio than their counterparts. During the convalescent period, the elevated HOMA-IR group had lower TNFα, IFNγ, IL-2, IL-10, and granzyme B expression levels but had higher TNFα/IL-10, IFNγ/IL-10, IL-2/IL-10, and granzyme B/IL-10 ratios than the other group. The reduced cytokine production and pro-/anti-inflammatory imbalance in patients with elevated HOMA-IR may suggest immune cell dysfunction toward SARS-CoV-2. Patients with elevated HOMA-IR after SARS-CoV-2 infection may experience an increase in BMI and body fat percentage, leading to increased immune dysfunction and chronic inflammatory condition. A nutritional approach and promotion of physical activity may help reduce HOMA-IR and ameliorate glucose indices in these patients. Full article
(This article belongs to the Special Issue Advanced Biomedical Research on COVID-19 (2nd Edition))
Show Figures

Figure 1

Figure 1
<p>Secretion levels of (<b>a</b>) TNFα, (<b>b</b>) IFNγ, (<b>c</b>) IL-2, (<b>d</b>) granzyme B, and (<b>e</b>) IL-10 detected from the SARS-CoV-2-stimulated supernatant obtained from convalescent COVID-19 patients. Black bars represent COVID-19 convalescent patients with non-elevated HOMA-IR, and gray bars represent those with elevated HOMA-IR. Acute phase indicates that the samples were obtained during acute COVID-19 infection. * <span class="html-italic">p</span> value &lt; 0.05 and ** <span class="html-italic">p</span> value &lt; 0.01. TNF-α, tumor necrosis factor α; IFNγ, interferon γ; IL-2, interleukin-2; IL-10, interleukin-10. All cytokine levels are presented as median (interquartile range) and were compared using the Mann–Whitney test.</p>
Full article ">Figure 2
<p>(<b>a</b>) TNFα/IL-10, (<b>b</b>) IFNγ/IL-10, (<b>c</b>) IL-2/IL-10, and (<b>d</b>) granzyme B/IL-10 ratios detected in the SARS-CoV-2-stimulated supernatant of the samples obtained from the convalescent COVID-19 patients. Black bars represent convalescent COVID-19 patients with non-elevated HOMA-IR, and gray bars represent those with elevated HOMA-IR. Acute phase indicates that the samples were obtained during acute COVID-19 infection. * <span class="html-italic">p</span> value &lt; 0.05 and ** <span class="html-italic">p</span> value &lt; 0.01. # <span class="html-italic">p</span> value &lt; 0.05 and ## <span class="html-italic">p</span> value &lt; 0.01 compared with the acute phase. TNF-α, tumor necrosis factor α; IFNγ, interferon γ; IL-2, interleukin-2; IL-10, interleukin-10. All cytokine levels are presented as median (interquartile range) and were compared using the Mann–Whitney test. Differences in IFNγ/IL-10 and L-2/IL-10 ratios between the acute phase and 3rd convalescent month were analyzed using the Wilcoxon signed-rank test.</p>
Full article ">
23 pages, 2541 KiB  
Article
Ketosis Suppression and Ageing (KetoSAge) Part 2: The Effect of Suppressing Ketosis on Biomarkers Associated with Ageing, HOMA-IR, Leptin, Osteocalcin, and GLP-1, in Healthy Females
by Isabella D. Cooper, Yvoni Kyriakidou, Lucy Petagine, Kurtis Edwards, Adrian Soto-Mota, Kenneth Brookler and Bradley T. Elliott
Biomedicines 2024, 12(7), 1553; https://doi.org/10.3390/biomedicines12071553 - 12 Jul 2024
Viewed by 1968
Abstract
Metabolic dysfunctions are among the best documented hallmarks of ageing. Cardiovascular disease, Alzheimer’s disease, cancer, type 2 diabetes mellitus, metabolic-dysfunction-associated steatosis liver disease, and fragility fractures are diseases of hyperinsulinaemia that reduce life and healthspan. We studied the effect of suppressing ketosis in [...] Read more.
Metabolic dysfunctions are among the best documented hallmarks of ageing. Cardiovascular disease, Alzheimer’s disease, cancer, type 2 diabetes mellitus, metabolic-dysfunction-associated steatosis liver disease, and fragility fractures are diseases of hyperinsulinaemia that reduce life and healthspan. We studied the effect of suppressing ketosis in 10 lean (BMI 20.5 kg/m2 ± 1.4), metabolically healthy, pre-menopausal women (age 32.3 ± 8.9 years) maintaining nutritional ketosis (NK) for an average of 3.9 years (± 2.3) who underwent three 21-day phases: nutritional ketosis (NK; P1), suppressed ketosis (SuK; P2), and returned to NK (P3). Ketosis suppression significantly increased insulin, 1.83-fold (p = 0.0006); glucose, 1.17-fold (p = 0.0088); homeostasis model assessment for insulin resistance (HOMA-IR), 2.13-fold (p = 0.0008); leptin, 3.35-fold (p = 0.0010); total osteocalcin, 1.63-fold (p = 0.0138); and uncarboxylated osteocalcin, 1.98-fold (p = 0.0417) and significantly decreased beta-hydroxybutyrate, 13.50-fold (p = 0.0012) and glucagon-like peptide-1 (GLP-1), 2.40-fold (p = 0.0209). Sustained NK showed no adverse health effects and may mitigate hyperinsulinemia. All biomarkers returned to basal P1 levels after removing the intervention for SuK, indicating that metabolic flexibility was maintained with long-term euketonaemia. Full article
Show Figures

Figure 1

Figure 1
<p>KetoSAge study design. Phase 1 and 3 covered the participants’ habitual nutritional ketosis lifestyle. Phase 2 was the interventional phase to suppress ketosis (SuK). Each phase was monitored via finger prick testing of capillary beta-hydroxybutyrate (BHB) concentration (mmol/L). Testing was conducted four times per day, prior to mealtimes, at evenly spaced intervals. At the end of each phase, participants underwent a laboratory testing day for body composition and biochemical tests. Participants were given an oral glucose tolerance test (75 g glucose in 250 mL water) described in our earlier publication [<a href="#B7-biomedicines-12-01553" class="html-bibr">7</a>]. Blood samples were taken at seven time points over 5 hours. Whole blood glucose and BHB were measured sequentially in real time using the Keto-Mojo<sup>TM</sup> meter, and plasma insulin sensitivity assay was conducted later using ELISA. Body mass index (BMI); oral glucose tolerance test (OGGT); respiratory quotient (RQ).</p>
Full article ">Figure 2
<p>Homeostatic model assessment for insulin resistance (HOMA-IR) across all phases in KetoSAge participants. Fasting serum concentrations of insulin and plasma glucose were measured following each of the study phases: baseline nutritional ketosis (NK), P1; intervention to suppress ketosis (SuK), P2; and removal of SuK returning to NK, P3. Insulin was determined by via Simple Plex Assay (Ella™, Bio-Techne, Minneapolis, USA) and glucose was measured by Biosen C-Line Clinic Glucose and Lactate analyser. HOMA-IR adopts the following formula to index insulin resistance: fasting plasma insulin (uIU/mL) × fasting plasma glucose (mmol/L)/22.5 [<a href="#B1-biomedicines-12-01553" class="html-bibr">1</a>,<a href="#B17-biomedicines-12-01553" class="html-bibr">17</a>,<a href="#B18-biomedicines-12-01553" class="html-bibr">18</a>]. Homeostasis model assessment for insulin resistance (HOMA-IR). Samples were taken at 8 a.m. after a 12 h overnight fast (n = 10). Data were analysed by repeated measures one-way ANOVA. ** <span class="html-italic">p</span> &lt; 0.01; and *** <span class="html-italic">p</span> &lt; 0.001.</p>
Full article ">Figure 3
<p>tOCN, cOCN, and unOCN across all phases in KetoSAge participants. Fasting plasma concentrations of (<b>A</b>) tOCN, (<b>B</b>) cOCN, and (<b>C</b>) unOCN were measured following each of the study phases: baseline nutritional ketosis (NK), P1; intervention to suppress ketosis (SuK), P2; and removal of SuK returning to NK, P3; total OCN (tOCN) and uncarboxylated OCN (unOCN) were determined by ELISA and carboxylated OCN (cOCN) was calculated by subtracting unOCN from tOCN. Samples were taken at 8 a.m. after a 12 h overnight fast; (n = 10); tOCN and cOCN data were analysed by repeated measures one-way ANOVA with Tukey’s correction for multiple comparisons, unOCN data were analysed using the Friedman test with Dunn’s correction for multiple comparisons. * <span class="html-italic">p</span> &lt; 0.05 and ** <span class="html-italic">p</span> &lt; 0.01.</p>
Full article ">Figure 4
<p>Percentage change from baseline P1 at 100% for tOCN, cOCN, and unOCN across all phases in KetoSAge participants. Fasting plasma concentrations of (<b>A</b>) tOCN, (<b>B</b>) cOCN, and (<b>C</b>) unOCN were measured following each of the study phases: baseline nutritional ketosis (NK), P1; intervention to suppress ketosis (SuK), P2; and removal of SuK returning to NK, P3; total OCN (tOCN) and uncarboxylated OCN (unOCN) were determined by ELISA, carboxylated OCN (cOCN) was calculated by subtracting unOCN from tOCN. Samples were taken at 8 a.m. after a 12 h overnight fast; (n = 10); data were analysed by repeated measures one-way ANOVA with Tukey’s correction for multiple comparisons. * <span class="html-italic">p</span> &lt; 0.05 and ** <span class="html-italic">p</span> &lt; 0.01.</p>
Full article ">Figure 5
<p>Serum leptin across all phases in KetoSAge participants. Fasting serum concentrations of leptin were measured following each of the study phases: baseline nutritional ketosis (NK), P1; intervention to suppress ketosis (SuK), P2; and removal of SuK returning to NK, P3. Leptin was determined by via ELISA (DuoSet, R&amp;D Systems, Minneapolis, MN, USA). Samples were taken at 8 a.m. after a 12 h overnight fast; (n = 10). Data were analysed by repeated measures one-way ANOVA. ** <span class="html-italic">p</span> &lt; 0.01.</p>
Full article ">Figure 6
<p>Serum cortisol and serotonin across all phases in KetoSAge participants. Fasting serum concentrations of cortisol and plasma serotonin were measured following each of the study phases: baseline nutritional ketosis (NK), P1; intervention to suppress ketosis (SuK), P2; and removal of SuK returning to NK, P3; cortisol was measured externally by SYNLAB Belgium (Alexander Fleming, 3–6220 Heppignies–Company No: 0453.111.546), serotonin was measured by ELISA (Abcam, Cambridge, UK). Samples were taken at 8 a.m. after a 12 h overnight fast; (n = 10). Data were analysed by Friedman test with Dunn’s correction for multiple comparisons.</p>
Full article ">Figure 7
<p>Serum concentrations of active GLP-1 across all phases in KetoSAge participants. Serum concentrations of active GLP-1 were measured following each of the study phases: baseline nutritional ketosis (NK), P1; intervention to suppress ketosis (SuK), P2; and removal of SuK returning to NK, P3. GLP-1 was determined by ELISA (Abcam, Cambridge, UK). Glucagon-like peptide-1 (GLP-1). Samples were taken at 8 a.m. after a 12 h overnight fast; (n = 10). Data were analysed by repeated measures one-way ANOVA. * <span class="html-italic">p</span> &lt; 0.05.</p>
Full article ">
21 pages, 364 KiB  
Article
Serum Levels of Adipolin and Adiponectin and Their Correlation with Perinatal Outcomes in Gestational Diabetes Mellitus
by Mihai Muntean, Vladut Săsăran, Sonia-Teodora Luca, Laura Mihaela Suciu, Victoria Nyulas and Claudiu Mărginean
J. Clin. Med. 2024, 13(14), 4082; https://doi.org/10.3390/jcm13144082 - 12 Jul 2024
Viewed by 600
Abstract
Objectives: This study aimed to investigate the serum level of adipolin and adiponectin in healthy pregnant women and pregnant women with gestational diabetes mellitus (GDM) during the second trimester, the prepartum period, and in the newborns of these patients. Methods: A [...] Read more.
Objectives: This study aimed to investigate the serum level of adipolin and adiponectin in healthy pregnant women and pregnant women with gestational diabetes mellitus (GDM) during the second trimester, the prepartum period, and in the newborns of these patients. Methods: A total of 55 women diagnosed with GDM and 110 healthy pregnant women were included in this study. Pearson’s and Spearman’s correlation coefficients were calculated to determine the association of adipolin and adiponectin with anthropometric markers of obesity (body mass index (BMI), mid-upper arm circumference (MUAC), tricipital skinfold thickness (TST)), inflammation markers (neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), C-reactive protein (CRP)), and maternal glucose homeostasis parameters (fasting glucose, insulin, C peptide, glycosylated hemoglobin A1c (HbA1c), Insulin Resistance—Homeostatic Model Assessment (IR HOMA)). Results: There were no statistical differences between the adipolin value in patients with GDM compared to healthy patients (p = 0.65 at diagnosis and p = 0.50 prepartum) and in newborns from mothers with GDM compared to healthy mothers (p = 0.24). Adipolin levels are significantly higher in patients with GDM who gave birth via cesarean section (p = 0.01). In patients with GDM, the adipolin level correlates positively with HgA1c in the prepartum period. We found a positive correlation between the maternal adipolin values at diagnosis and prepartum and neonatal adipolin (respectively: r = 0.556, p = 0.001; r = 0.332, p = 0.013). Adiponectin levels were significantly lower in patients with GDM at diagnosis and prepartum (p = 0.0009 and p = 0.02), but their levels increased prepartum (5267 ± 2114 ng/mL vs. 6312 ± 3150 ng/mL p = 0.0006). Newborns of mothers with GDM had lower adiponectin levels than newborns of healthy mothers (p < 0.0001). The maternal adiponectin value correlates negatively with maternal BMI, MUAC, and IR HOMA in both groups at diagnosis and prepartum. There were no differences between the groups in terms of cesarean rate (p > 0.99). The relative risk of occurrence of adverse events in patients with GDM compared to healthy ones was 2.15 (95% CI 1.416 to 3.182), and the odds ratio for macrosomia was 4.66 (95% CI 1.591 to 12.69). Conclusions: There was no difference in adipolin levels between mothers with GDM and healthy mothers during the second trimester and the prepartum period. Adipolin is known to enhance insulin sensitivity and reduce inflammation, but unlike adiponectin, it does not appear to contribute to the development of GDM. Full article
(This article belongs to the Special Issue Gestational Diabetes: Current Knowledge and Therapeutic Prospects)
15 pages, 453 KiB  
Article
The Effects of Flaxseed Consumption on Glycemic Control in Native American Postmenopausal Women with Hyperglycemia and Hyperlipidemia
by Ines Ellouze, Kiranmayi Korlagunta, Edralin A. Lucas, Mark Payton, Saiful Singar and Bahram H. Arjmandi
Healthcare 2024, 12(14), 1392; https://doi.org/10.3390/healthcare12141392 - 11 Jul 2024
Viewed by 583
Abstract
Glucose control in postmenopausal women is influenced by many factors, such as hormones, lifestyle variables, and genetics. Limited data exist on the effect of whole flaxseed on glucose status in postmenopausal Native American women. The aim of this study was to investigate the [...] Read more.
Glucose control in postmenopausal women is influenced by many factors, such as hormones, lifestyle variables, and genetics. Limited data exist on the effect of whole flaxseed on glucose status in postmenopausal Native American women. The aim of this study was to investigate the glucose management effect of a flaxseed dietary intervention on postmenopausal Native American women. In this study, 55 Native American postmenopausal women (aged 47–63 years) with borderline hyperglycemia (>100 and <126 mg/dL) and mild to moderate hypercholestorolemia (≥200 to ≤380 mmol/L), who were not on hormone replacement therapy, were enrolled. Participants were randomly assigned to one of the three dietary regimens (control, flaxseed, and flaxseed + fiber) for three months, receiving interventions in the form of bread, muffins, and flaxseed powder. Despite daily consumption of flaxseed across diverse food formats, no significant changes in glucose (p = 0.3, p = 0.2), insulin levels (p = 0.59, p = 0.9), or HOMA-IR (p = 0.84, p = 0.66) were observed compared to their respective baseline values within the flaxseed and flaxseed + fiber groups, respectively. Conversely, the control group showed a significant rise in final glucose values from baseline (p = 0.01). However, the incorporation of ground flaxseed into low-glycemic foods holds potential for beneficial effects through maintaining glucose status among postmenopausal Native American women. This research provides critical insights into the effects of flaxseed, emphasizing the need for continued exploration to understand its role in supporting glucose management among postmenopausal Native American women. Further exploration is required to investigate the potential long-term impact and the use of flaxseed in managing glucose levels in this demographic. Full article
Show Figures

Figure 1

Figure 1
<p>Study design of the randomized controlled trial of flaxseed supplementation.</p>
Full article ">
24 pages, 3506 KiB  
Article
The Impact of Cornelian Cherry (Cornus mas L.) on Cardiometabolic Risk Factors: A Meta-Analysis of Randomised Controlled Trials
by Oleg Frumuzachi, Helena Kieserling, Sascha Rohn, Andrei Mocan and Gianina Crișan
Nutrients 2024, 16(13), 2173; https://doi.org/10.3390/nu16132173 - 8 Jul 2024
Viewed by 1410
Abstract
This meta-analysis aimed to summarise clinical evidence regarding the effect of supplementation with cornelian cherry (Cornus mas L.) on different cardiometabolic outcomes. An extensive literature survey was carried out until 10 April 2024. A total of 415 participants from six eligible studies [...] Read more.
This meta-analysis aimed to summarise clinical evidence regarding the effect of supplementation with cornelian cherry (Cornus mas L.) on different cardiometabolic outcomes. An extensive literature survey was carried out until 10 April 2024. A total of 415 participants from six eligible studies were included. The overall results from the random-effects model indicated that cornelian cherry supplementation significantly reduced body weight (standardised mean difference [SMD] = −0.27, confidence interval [CI]: −0.52, −0.02, p = 0.03), body mass index (SMD = −0.42, CI: −0.73, −0.12, p = 0.007), fasting blood glucose (SMD = −0.46, CI: −0.74, −0.18, p = 0.001), glycated haemoglobin (SMD = −0.70, CI: −1.19, −0.22, p = 0.005), and HOMA-IR (SMD = −0.89, CI: −1.62, −0.16, p = 0.02), while high-density lipoprotein cholesterol significantly increased (SMD = 0.38, CI: 0.10, 0.65, p = 0.007). A sensitivity analysis showed that cornelian cherry supplementation significantly reduced total plasma triglycerides, total cholesterol, low-density lipoprotein cholesterol, and insulin levels. Cornelian cherry supplementation did not significantly affect waist circumference and liver parameters among the participants. Considering these findings, this meta-analysis indicates that supplementation with cornelian cherry may impact diverse cardiometabolic risk factors among individuals considered to be at a high risk. Full article
(This article belongs to the Special Issue Endocrinology, Diabetes, and Clinical Nutrition)
Show Figures

Graphical abstract

Graphical abstract
Full article ">Figure 1
<p>The PRISMA flowchart depicting the study selection process.</p>
Full article ">Figure 2
<p>The evaluation of risk of bias concerning each aspect across the studies included in the meta-analysis. D1—randomisation process, D2—deviations from intended interventions, D3—missing outcome data, D4—measurement of the outcome, and D5—selection of the reported results [<a href="#B28-nutrients-16-02173" class="html-bibr">28</a>,<a href="#B29-nutrients-16-02173" class="html-bibr">29</a>,<a href="#B30-nutrients-16-02173" class="html-bibr">30</a>,<a href="#B31-nutrients-16-02173" class="html-bibr">31</a>,<a href="#B32-nutrients-16-02173" class="html-bibr">32</a>,<a href="#B33-nutrients-16-02173" class="html-bibr">33</a>].</p>
Full article ">Figure 3
<p>Risk of bias across individual elements, presented as percentage (intention-to-treat), for studies included in the meta-analysis.</p>
Full article ">Figure 4
<p>Forest plot representation of RCTs exploring the impact of cornelian cherry supplementation on anthropometric measurements ((<b>A</b>): body weight, (<b>B</b>): BMI, and (<b>C</b>): waist circumference) [<a href="#B28-nutrients-16-02173" class="html-bibr">28</a>,<a href="#B29-nutrients-16-02173" class="html-bibr">29</a>,<a href="#B30-nutrients-16-02173" class="html-bibr">30</a>,<a href="#B32-nutrients-16-02173" class="html-bibr">32</a>,<a href="#B33-nutrients-16-02173" class="html-bibr">33</a>].</p>
Full article ">Figure 5
<p>Forest plot representation of RCTs exploring the impact of cornelian cherry supplementation on blood lipid levels ((<b>A</b>): total triglycerides, (<b>B</b>): total cholesterol, (<b>C</b>): LDL-C, and (<b>D</b>): HDL-C) [<a href="#B28-nutrients-16-02173" class="html-bibr">28</a>,<a href="#B29-nutrients-16-02173" class="html-bibr">29</a>,<a href="#B30-nutrients-16-02173" class="html-bibr">30</a>,<a href="#B33-nutrients-16-02173" class="html-bibr">33</a>].</p>
Full article ">Figure 6
<p>Forest plot representation of RCTs exploring the impact of cornelian cherry supplementation on glycaemic parameters ((<b>A</b>): fasting blood glucose, (<b>B</b>): insulin, (<b>C</b>): HbA1c, and (<b>D</b>): HOMA-IR) [<a href="#B28-nutrients-16-02173" class="html-bibr">28</a>,<a href="#B29-nutrients-16-02173" class="html-bibr">29</a>,<a href="#B30-nutrients-16-02173" class="html-bibr">30</a>,<a href="#B33-nutrients-16-02173" class="html-bibr">33</a>].</p>
Full article ">Figure 7
<p>Forest plot representation of RCTs exploring the impact of cornelian cherry supplementation on liver parameters ((<b>A</b>): AST and (<b>B</b>): ALT) [<a href="#B28-nutrients-16-02173" class="html-bibr">28</a>,<a href="#B29-nutrients-16-02173" class="html-bibr">29</a>,<a href="#B31-nutrients-16-02173" class="html-bibr">31</a>].</p>
Full article ">
29 pages, 1043 KiB  
Review
Inquiry of the Metabolic Traits in Relationship with Daily Magnesium Intake: Focus on Type 2 Diabetic Population
by Ana-Maria Gheorghe, Mihai-Lucian Ciobica, Claudiu Nistor, Maria-Magdalena Gurzun, Bianca-Andreea Sandulescu, Mihaela Stanciu, Florina Ligia Popa and Mara Carsote
Clin. Pract. 2024, 14(4), 1319-1347; https://doi.org/10.3390/clinpract14040107 - 8 Jul 2024
Viewed by 550
Abstract
Magnesium (Mg), an essential nutrient with a wide area of physiological roles, stands as a cofactor in over 600 enzymatic reactions involved in the synthesis of proteins and nucleic acids, DNA repair, neuromuscular functions, neuronal transmission, cardiac rhythm regulation, and the modulation of [...] Read more.
Magnesium (Mg), an essential nutrient with a wide area of physiological roles, stands as a cofactor in over 600 enzymatic reactions involved in the synthesis of proteins and nucleic acids, DNA repair, neuromuscular functions, neuronal transmission, cardiac rhythm regulation, and the modulation of metabolic pathways, as well as acting as a natural blocker for the calcium channels. Our objective was to highlight the most recent clinical data with respect to daily Mg intake (DMI) and metabolic traits, particularly type 2 diabetes mellitus (DM). This was a PubMed-based review of the English-language medical papers across different key terms of search; the time frame was from January 2019 until April 2024. We included (clinically relevant) original studies and excluded cases reports, series, reviews, editorials, opinion, experimental studies, and non-human data as well as studies that did not specifically assessed DMI and only provided assays of serum Mg, studies on patients diagnosed with type 1 or secondary DM. A total of 30 studies were included and we organized the key findings into several sections as follows. Studies investigating DMI in relationship with the adherence to local recommendations in diabetic subjects (n = 2, one transversal and another retrospective cohort; N = 2823) found that most of them had lower DMI. Deficient DMI was correlated with the risk of developing/having DM across five studies (n = 5, one prospective and four of cross-sectional design; N = 47,166). An inverse correlation between DMI and DM prevalence was identified, but these data are presented amid a rather heterogeneous spectrum. Four novel studies (N = 7279) analysed the relationship between DMI and DM control according to various methods (HbA1c, fasting and postprandial glycaemia, and insulin); the association may be linear in diabetic subjects only at certain levels of DMI; additionally, the multifactorial influence on HBA1c should take into consideration this dietary determinant, as well, but there are no homogenous results. Three studies concerning DMI and diabetic complications (one cross-sectional, one prospective, and another case–control study) in terms of retinopathy (n = 1, N = 3794) and nephropathy (n = 2, N = 4805) suggested a lower DMI was associated with a higher risk of such complications. Additionally, two other studies (one prospective and one retrospective cohort) focused on mortality (N = 6744), which, taking only certain mortality indicators into consideration, might be decreased in the subgroups with a higher DMI. Seven studies (N = 30,610) analysed the perspective of DMI in the general population with the endpoint of different features amid glucose profile, particularly, insulin resistance. Concerning HOMA-IR, there were three confirmatory studies and one non-confirmatory, while fasting plasma glucose was highlighted as inversely correlated with a DMI (n = 1). The highest level of evidence regarding Mg supplementation effects on glucose metabolism stands on seven randomised controlled trials (N = 350). However, the sample size was reduced (from 14 to 86 individuals per study, either diabetic or pre-diabetic) and outcomes were rather discordant. These clinical aspects are essential from a multidisciplinary perspective and further trials are mandatory to address the current areas of discordant results. Full article
(This article belongs to the Special Issue Clinical Nutrition in Metabolic Disorders)
Show Figures

Figure 1

Figure 1
<p>Magnesium regulates by being an enzyme co-factor insulin secretion and receptor effects as well as oxidative stress and inflammatory profile, all of which might be impaired amid the detection of type 2 diabetes [<a href="#B22-clinpract-14-00107" class="html-bibr">22</a>,<a href="#B23-clinpract-14-00107" class="html-bibr">23</a>,<a href="#B24-clinpract-14-00107" class="html-bibr">24</a>,<a href="#B25-clinpract-14-00107" class="html-bibr">25</a>].</p>
Full article ">Figure 2
<p>The key findings across selected studies according to the mentioned methods.</p>
Full article ">Figure 3
<p>Sneak peak of magnesium interplay and type 2 diabetes mellitus amid the co-presence of metabolic syndrome and associated high cardiovascular risk.</p>
Full article ">
16 pages, 1009 KiB  
Systematic Review
The Triglyceride/HDL Ratio as a Surrogate Biomarker for Insulin Resistance
by Petru Baneu, Cristina Văcărescu, Simona-Ruxanda Drăgan, Liviu Cirin, Alexandra-Iulia Lazăr-Höcher, Andreea Cozgarea, Adelina-Andreea Faur-Grigori, Simina Crișan, Dan Gaiță, Constantin-Tudor Luca and Dragoș Cozma
Biomedicines 2024, 12(7), 1493; https://doi.org/10.3390/biomedicines12071493 - 5 Jul 2024
Viewed by 659
Abstract
Given the widespread occurrence of insulin resistance, a key factor in metabolic syndrome and a distinct condition altogether, there is a clear need for effective, surrogate markers. The triglyceride-to-high-density lipoprotein (TG/HDL) ratio stands out as a viable option, indicative of changes in lipid [...] Read more.
Given the widespread occurrence of insulin resistance, a key factor in metabolic syndrome and a distinct condition altogether, there is a clear need for effective, surrogate markers. The triglyceride-to-high-density lipoprotein (TG/HDL) ratio stands out as a viable option, indicative of changes in lipid metabolism associated with insulin resistance, offering a cost-effective and straightforward alternative to traditional, more complex biomarkers. This review, in line with PRISMA guidelines, assesses the TG/HDL ratio’s potential as an indirect indicator of insulin resistance. Analysing 32 studies over 20 years, involving 49,782 participants of diverse ethnic backgrounds, including adults and children, this review primarily uses a cross-sectional analysis with the Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) to gauge insulin resistance. It reveals the TG/HDL ratio’s varied predictive power across ethnicities and sexes, with specific thresholds providing greater accuracy for Caucasians, Asians, and Hispanics over African Americans and for men over women. Valid across different weights and ages, for adults and children, it suggests average cutoffs of 2.53 for women and 2.8 for men. The analysis supports the TG/HDL ratio as a simple, accessible marker for insulin resistance, though it advises further research on tailored cutoffs reflecting ethnic and gender differences. Full article
Show Figures

Figure 1

Figure 1
<p>Search strategy employed in this review.</p>
Full article ">Figure 2
<p>AUC-ROC for the predictive value of the TG/HDL ratio [<a href="#B7-biomedicines-12-01493" class="html-bibr">7</a>,<a href="#B9-biomedicines-12-01493" class="html-bibr">9</a>,<a href="#B10-biomedicines-12-01493" class="html-bibr">10</a>,<a href="#B13-biomedicines-12-01493" class="html-bibr">13</a>,<a href="#B14-biomedicines-12-01493" class="html-bibr">14</a>,<a href="#B16-biomedicines-12-01493" class="html-bibr">16</a>,<a href="#B17-biomedicines-12-01493" class="html-bibr">17</a>,<a href="#B19-biomedicines-12-01493" class="html-bibr">19</a>,<a href="#B20-biomedicines-12-01493" class="html-bibr">20</a>,<a href="#B25-biomedicines-12-01493" class="html-bibr">25</a>,<a href="#B29-biomedicines-12-01493" class="html-bibr">29</a>,<a href="#B31-biomedicines-12-01493" class="html-bibr">31</a>,<a href="#B33-biomedicines-12-01493" class="html-bibr">33</a>,<a href="#B34-biomedicines-12-01493" class="html-bibr">34</a>,<a href="#B37-biomedicines-12-01493" class="html-bibr">37</a>,<a href="#B38-biomedicines-12-01493" class="html-bibr">38</a>].</p>
Full article ">
18 pages, 776 KiB  
Article
Evaluation of Fasting Glucose-Insulin-C-Peptide-Derived Metabolic Indices for Identifying Metabolic Syndrome in Young, Healthy Adults
by Irina Bianca Kosovski, Dana Ghiga, Cristina Nicoleta Ciurea, Dragos Constantin Cucoranu, Liliana Demian, Florina Ioana Gliga and Anca Bacârea
Nutrients 2024, 16(13), 2135; https://doi.org/10.3390/nu16132135 - 4 Jul 2024
Viewed by 1079
Abstract
Metabolic syndrome (MetS) is a condition defined by a cluster of symptoms, including excessive adipose tissue, impaired glucose homeostasis, dyslipidemia, and high blood pressure (BP). We aimed to evaluate the correlation between the MetS criteria (IDF) and fasting glucose-insulin-C-peptide-derived indices in a cohort [...] Read more.
Metabolic syndrome (MetS) is a condition defined by a cluster of symptoms, including excessive adipose tissue, impaired glucose homeostasis, dyslipidemia, and high blood pressure (BP). We aimed to evaluate the correlation between the MetS criteria (IDF) and fasting glucose-insulin-C-peptide-derived indices in a cohort of 128 healthy young adults who were 20–35 years old at the time of this study. We measured fasting serum glucose, insulin, C-peptide (CP), HDL-cholesterol, triglycerides, and hsCRP; HOMA-IR INS, HOMA-IR CP1, HOMA-IR CP2, HOMA-BETA, HOMA-BETA CP, QUICKI, disposition index (DI), CP index (CPI), and 20/C-peptide*glucose. Significant correlations were found between BMI and all HOMA indices, QUICKI, and CPI; waist circumferences and HOMA-IR INS, HOMA-BETA, and QUICKI (for both sexes); glucose and HOMA-IR INS/CP1/CP2, HOMA-BETA CP, DI, and QUICKI; HDL-cholesterol and HOMA-IR INS, HOMA-BETA, and QUICKI for males and females only with QUICKI; triglycerides and HOMA-IR INS, HOMA-BETA, and QUICKI; systolic BP and HOMA-IR INS, HOMA-BETA; diastolic BP and DI. The cut-off values for HOMA-IR INS, HOMA-BETA, and QUICKI in the combined group (females + males) were 1.855, 82.250, 0.355; 2.115, 106.370, 0.345 for males; 1.805, 71.305, 0.355 for females. A stronger correlation was found between males’ indices and hsCRP. In conclusion, CP-derived indices do not add significant information, and the male sex is more predisposed to MetS. Full article
(This article belongs to the Special Issue Nutritional Factors and Adipose Tissue in Metabolic Syndrome)
Show Figures

Figure 1

Figure 1
<p>Receiver operating characteristic (ROC) curve for HOMA-IR INS, HOMA-BETA, and QUICKI to determine MetS. HOMA-IR INS: the homeostasis model assessment-estimated insulin resistance, insulin derived index; HOMA-BETA: the homeostasis model assessment of β-cell function; QUICKI: the quantitative insulin sensitivity check index; AUC: Area Under the Curve; 95% CI: confidence interval of 95%.</p>
Full article ">
Back to TopTop